MX356433B - Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos. - Google Patents
Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos.Info
- Publication number
- MX356433B MX356433B MX2013015324A MX2013015324A MX356433B MX 356433 B MX356433 B MX 356433B MX 2013015324 A MX2013015324 A MX 2013015324A MX 2013015324 A MX2013015324 A MX 2013015324A MX 356433 B MX356433 B MX 356433B
- Authority
- MX
- Mexico
- Prior art keywords
- polypeptide
- methods
- fusion polypeptides
- domain fusion
- wap domain
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title abstract 10
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 10
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 10
- 230000004927 fusion Effects 0.000 title 1
- 101710087237 Whey acidic protein Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000009027 Albumins Human genes 0.000 abstract 1
- 108010088751 Albumins Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 108050000761 Serpin Proteins 0.000 abstract 1
- 102000008847 Serpin Human genes 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8121—Serpins
- C07K14/8125—Alpha-1-antitrypsin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/241—Tumor Necrosis Factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se refiere a una proteína de fusión aislada, caracterizada porque comprende por lo menos un polipéptido inhibidor secretorio de la proteinasa de los leucocitos (SLPI) de humano que comprende la secuencia de aminoácidos de SEQ ID NO: 1, SEQ ID NO:2, SEQ ID NO.3, o SEQ ID NO: 39 enlazado operablemente a un polipéptido de Fc de inmunoglobulina que comprende la secuencia de aminoácidos de SEQ ID NO: 10.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161502052P | 2011-06-28 | 2011-06-28 | |
US201161565625P | 2011-12-01 | 2011-12-01 | |
US201261638168P | 2012-04-25 | 2012-04-25 | |
US201261638516P | 2012-04-26 | 2012-04-26 | |
PCT/US2012/044742 WO2013003649A2 (en) | 2011-06-28 | 2012-06-28 | Wap domain fusion polypeptides and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013015324A MX2013015324A (es) | 2014-05-01 |
MX356433B true MX356433B (es) | 2018-05-29 |
Family
ID=47424808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013015324A MX356433B (es) | 2011-06-28 | 2012-06-28 | Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (2) | US8986688B2 (es) |
EP (1) | EP2726093A4 (es) |
JP (1) | JP2014528913A (es) |
KR (1) | KR20140068861A (es) |
CN (1) | CN103946388A (es) |
AU (2) | AU2012275295B2 (es) |
BR (1) | BR112013033801A2 (es) |
CA (1) | CA2839622A1 (es) |
IN (1) | IN2013MN02442A (es) |
MX (1) | MX356433B (es) |
RU (1) | RU2639526C2 (es) |
WO (1) | WO2013003649A2 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6216921B2 (ja) | 2011-06-24 | 2017-11-01 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド,ア ボディー コーポレイトTHE REGENTS OF THE UNIVERSITY OF COLORADO,a body corporate | アルファ−1抗トリプシン融合分子のための組成物、方法および使用 |
WO2013003641A2 (en) | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
CN103946388A (zh) | 2011-06-28 | 2014-07-23 | 英伊布里克斯有限责任公司 | Wap结构域融合多肽及其使用方法 |
US10478508B2 (en) * | 2012-01-10 | 2019-11-19 | The Regents Of The University Of Colorado, A Body Corporate | Compositions, methods and uses for alpha-1 antitrypsin fusion molecules |
EP2969009B1 (en) * | 2013-03-15 | 2018-11-28 | Pyranose Biotherapeutics, Inc. | Modified fc fusion proteins |
CN103804484B (zh) * | 2014-01-24 | 2016-03-16 | 南京必优康生物技术有限公司 | 一种网红细胞生长因子及其制备方法和应用 |
CA2926231C (en) | 2014-07-23 | 2022-10-04 | Inova Diagnostics, Inc. | Compositions and methods for the diagnosis of rheumatoid arthritis |
UA127305C2 (uk) * | 2014-10-27 | 2023-07-19 | ІНГІБРЕКС, Інк. | Злитий серпіновий поліпептид і спосіб його застосування |
MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
WO2017192580A1 (en) * | 2016-05-02 | 2017-11-09 | The Regents Of The University Of California | Novel fusion proteins for treating inflammatory diseases |
US10839195B2 (en) * | 2017-08-08 | 2020-11-17 | Uchicago Argonne, Llc | Machine learning technique to identify grains in polycrystalline materials samples |
US11663494B2 (en) | 2019-12-05 | 2023-05-30 | Uchicago Argonne, Llc | Systems and methods for hierarchical multi-objective optimization |
CN110964094B (zh) * | 2019-12-20 | 2021-11-02 | 华中科技大学 | 人源白细胞蛋白酶抑制因子及其重组制备与应用 |
US11651839B2 (en) | 2020-03-02 | 2023-05-16 | Uchicago Argonne, Llc | Systems and methods for generating phase diagrams for metastable material states |
US11710038B2 (en) | 2020-04-13 | 2023-07-25 | Uchicago Argonne, Llc | Systems and methods for active learning from sparse training data |
KR20230093483A (ko) * | 2020-10-29 | 2023-06-27 | 포르미콘 아게 | Ace2 융합 단백질 및 이의 용도 |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5734014A (en) * | 1992-08-11 | 1998-03-31 | Tsumura & Co. | Elafin derivative |
TW575567B (en) * | 1998-10-23 | 2004-02-11 | Akzo Nobel Nv | Serine protease inhibitor |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
CA2364471A1 (en) * | 1999-03-01 | 2000-09-08 | Human Genome Sciences, Inc. | Human serpin proteins |
EP1244685A4 (en) * | 1999-12-01 | 2003-05-07 | Human Genome Sciences Inc | FOUR POLYNUCLEOTIDES CONTAINING A DISULFIDE CORE DOMAIN (FDCD), POLYPEPTIDES, AND ANTIBODIES |
FR2814957B1 (fr) * | 2000-10-06 | 2002-12-20 | Aventis Pasteur | Composition vaccinale et procede de stabilisation |
IL155812A0 (en) * | 2000-12-07 | 2003-12-23 | Lilly Co Eli | Glp-1 fusion proteins |
DK1355919T3 (da) * | 2000-12-12 | 2011-03-14 | Medimmune Llc | Molekyler med længere halveringstider, sammensætninger og anvendelser deraf |
US7247704B2 (en) * | 2000-12-18 | 2007-07-24 | Arriva Pharmaceuticals, Inc. | Multifunctional protease inhibitors and their use in treatment of disease |
US7270960B2 (en) * | 2001-08-29 | 2007-09-18 | Pacific Northwest Research Institute | Diagnosis of ovarian carcinomas |
DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
CN103212084B (zh) * | 2003-11-13 | 2018-07-13 | 韩美科学株式会社 | 含有免疫球蛋白fc区作为载体的药物组合物 |
US8110665B2 (en) | 2003-11-13 | 2012-02-07 | Hanmi Holdings Co., Ltd. | Pharmaceutical composition comprising an immunoglobulin FC region as a carrier |
AU2005221151A1 (en) * | 2004-03-09 | 2005-09-22 | Arriva Pharmaceuticals, Inc. | Treatment of chronic obstructive pulmonary disease by low dose inhalation of protease inhibitor |
WO2006017647A1 (en) * | 2004-08-03 | 2006-02-16 | Transtech Pharma, Inc. | Rage fusion proteins and methods of use |
US7399746B2 (en) * | 2004-10-06 | 2008-07-15 | Mcgill University | Agents for wound healing |
EP1868650B1 (en) * | 2005-04-15 | 2018-10-03 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
WO2006130834A2 (en) | 2005-05-31 | 2006-12-07 | Board Of Regents, The University Of Texas System | IGGl ANTIBODIES WITH MUTATED FC PORTION FOR INCREASED BINDING TO FCRN RECEPTOR AND USES THEREOF |
JP4067557B2 (ja) | 2005-06-03 | 2008-03-26 | 持田製薬株式会社 | 抗cd14抗体融合蛋白質 |
JP2009532369A (ja) * | 2006-03-30 | 2009-09-10 | リサーチ ファウンデーション オブ シティ ユニバーシティ オブ ニューヨーク | 分泌性白血球プロテアーゼインヒビターによる神経再生の刺激 |
GB0614780D0 (en) * | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
WO2008077478A1 (en) * | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Preparation and use of variants of the kunitz domain 2 of the human placental bikunin gene |
WO2009045508A1 (en) * | 2007-10-02 | 2009-04-09 | Research Foundation Of City University Of New York | Novel protein transduction domains derived from secretory leukocyte protease inhibitor |
AR064713A1 (es) * | 2007-12-28 | 2009-04-22 | Consejo Nac Invest Cient Tec | Proteina de fusion que se une a transglutaminasas , composiciones que la comprenden , micro- esferas que la comprenden, usos y metodos |
SE533763C2 (sv) * | 2009-05-04 | 2010-12-28 | Lars Hammar | Upphängningsanordning |
GB201003559D0 (en) | 2010-03-03 | 2010-04-21 | Proteo Biotech Ag | Novel use of elafin |
WO2013003641A2 (en) * | 2011-06-28 | 2013-01-03 | Inhibrx Llc | Serpin fusion polypeptides and methods of use thereof |
CN103946388A (zh) * | 2011-06-28 | 2014-07-23 | 英伊布里克斯有限责任公司 | Wap结构域融合多肽及其使用方法 |
US10400029B2 (en) * | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
-
2012
- 2012-06-28 CN CN201280041897.1A patent/CN103946388A/zh active Pending
- 2012-06-28 MX MX2013015324A patent/MX356433B/es active IP Right Grant
- 2012-06-28 BR BR112013033801A patent/BR112013033801A2/pt not_active IP Right Cessation
- 2012-06-28 IN IN2442MUN2013 patent/IN2013MN02442A/en unknown
- 2012-06-28 US US13/536,987 patent/US8986688B2/en active Active
- 2012-06-28 WO PCT/US2012/044742 patent/WO2013003649A2/en active Application Filing
- 2012-06-28 AU AU2012275295A patent/AU2012275295B2/en not_active Ceased
- 2012-06-28 CA CA2839622A patent/CA2839622A1/en not_active Abandoned
- 2012-06-28 RU RU2014102585A patent/RU2639526C2/ru not_active IP Right Cessation
- 2012-06-28 JP JP2014519054A patent/JP2014528913A/ja active Pending
- 2012-06-28 KR KR1020147002362A patent/KR20140068861A/ko not_active Application Discontinuation
- 2012-06-28 EP EP12804947.5A patent/EP2726093A4/en not_active Ceased
-
2015
- 2015-02-06 US US14/616,351 patent/US9914765B2/en active Active
-
2017
- 2017-02-10 AU AU2017200928A patent/AU2017200928A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN103946388A (zh) | 2014-07-23 |
NZ619035A (en) | 2015-07-31 |
US20130011399A1 (en) | 2013-01-10 |
BR112013033801A2 (pt) | 2017-12-19 |
WO2013003649A2 (en) | 2013-01-03 |
JP2014528913A (ja) | 2014-10-30 |
IN2013MN02442A (es) | 2015-06-12 |
CA2839622A1 (en) | 2013-01-03 |
MX2013015324A (es) | 2014-05-01 |
RU2014102585A (ru) | 2015-08-10 |
RU2639526C2 (ru) | 2017-12-21 |
WO2013003649A3 (en) | 2013-03-21 |
US8986688B2 (en) | 2015-03-24 |
AU2012275295A1 (en) | 2014-01-16 |
AU2017200928A1 (en) | 2017-03-02 |
EP2726093A4 (en) | 2015-08-19 |
US20150147324A1 (en) | 2015-05-28 |
AU2012275295B2 (en) | 2016-11-10 |
EP2726093A2 (en) | 2014-05-07 |
KR20140068861A (ko) | 2014-06-09 |
US9914765B2 (en) | 2018-03-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX356433B (es) | Polipéptidos de fusión con domino de proteína ácida del suero, y métodos de uso de los mismos. | |
MX2013015323A (es) | Polipeptidos de fusion de serpina y metodos de uso de los mismos. | |
MX2021012047A (es) | Polipeptidos de fusion de serpina y metodos para utilizar los mismos. | |
PH12020550205A1 (en) | IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USE | |
BR112019001108A2 (pt) | usos de vesículas extracelulares compreendendo uma proteína de fusão tendo capacidade de ligação a fc | |
TN2012000518A1 (en) | Serum albumin binding molecules | |
EA202090216A2 (ru) | Связывающие сывороточный альбумин домены фибронектина iii типа | |
AU2015269210A8 (en) | Methods of constructing amino terminal immunoglobulin fusion proteins and compositions thereof | |
TW201613958A (en) | MIC-1 fusion proteins and uses thereof | |
WO2013184939A3 (en) | Fusion polypeptides comprising an active protein linked to a mucin-domain polypeptide | |
MA40882A (fr) | Molécules de liaison d'antigène comprenant un trimère de ligand de la famille tnf | |
MX350962B (es) | Metodo para fabricar moleculas heterodimericas de fragmentos cristalizables de anticuerpo, utilizando efectos electrostaticos de direccion. | |
WO2014100439A3 (en) | B7-h4 specific antibodies, and compositions and methods of use thereof | |
WO2012109624A3 (en) | Monovalent and multivalent multispecific complexes and uses thereof | |
WO2013075066A3 (en) | Variant serum albumin with improved half -life and other properties | |
WO2017053619A8 (en) | Glypican-3binding fibronectin based scafflold molecules | |
TR201905619T4 (tr) | Alerji aşısı olarak peptit taşıyıcı füzyon proteinleri. | |
WO2008157378A8 (en) | Rage fusion proteins | |
WO2011064758A3 (en) | Fusion proteins of immunoglobulin fc and interferon- alpha | |
MX366178B (es) | Proteinas de btnl3, acidos nucleicos, y anticuerpos y los usos de los mismos. | |
MX2017014397A (es) | Anticuerpos anti-receptor neonatal de fragmento cristalizable(fcrn). | |
MX2021000155A (es) | Moleculas de proteina multifuncionales que comprenden decorina y su uso. | |
WO2014144621A3 (en) | Modified fc fusion proteins | |
NZ724196A (en) | Uti fusion proteins | |
WO2015001013A3 (en) | Human anti-ifn-alpha antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
HC | Change of company name or juridical status |
Owner name: IMFLUX, INC. |